Cascade Investment Advisors Inc. Has $1.67 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Cascade Investment Advisors Inc. raised its stake in Sanofi (NASDAQ:SNYFree Report) by 4.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 34,359 shares of the company’s stock after purchasing an additional 1,535 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Sanofi were worth $1,670,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Boston Partners increased its stake in Sanofi by 1.9% in the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after buying an additional 245,682 shares during the period. Morgan Stanley grew its position in Sanofi by 4.6% in the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after acquiring an additional 323,968 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after acquiring an additional 651,756 shares in the last quarter. Natixis Advisors L.P. grew its position in Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock worth $135,618,000 after acquiring an additional 346,563 shares in the last quarter. Finally, Raymond James & Associates grew its position in Sanofi by 26.9% in the first quarter. Raymond James & Associates now owns 2,315,255 shares of the company’s stock worth $112,521,000 after acquiring an additional 491,498 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY traded down $1.36 during trading hours on Thursday, hitting $49.00. 2,781,512 shares of the stock were exchanged, compared to its average volume of 1,993,655. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The company’s 50 day moving average is $48.27 and its 200 day moving average is $48.20. The firm has a market capitalization of $123.95 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.52 and a beta of 0.61. Sanofi has a one year low of $42.63 and a one year high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.96. The business had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. On average, research analysts expect that Sanofi will post 4.12 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 74.37%.

Wall Street Analyst Weigh In

Several research firms have commented on SNY. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Read Our Latest Analysis on SNY

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.